Corporate · Global B2B
●Evidence & Validation

Publications and technical resources, organized for review.

X-ZELL evidence across a foundational 2018 methods paper, the MVZ Frankfurt time-motion study, IOL Ljubljana FNA preliminary results, and 2026 Cryophore validation.

Selected evidence

Evidence timeline.

2018

Seven-fluorophore widefield IF method

Bhakdi SC, Thaicharoen P. Methods Protoc. 2018;1(2):20

Foundational method paper for crosstalk-free detection of seven fluorophores in widefield fluorescence microscopy.

Open DOI →
2023

MVZ Frankfurt time-motion study

Grote, Bhakdi, Thaicharoen, Battmann. X-ZELL Research Report 2023

Deck source for turnaround, handling, data-yield, and workflow-consolidation figures.

View performance →
2026

IOL Ljubljana FNA preliminary results

Miceska et al., Institute of Oncology Ljubljana

Peer-reviewed preliminary report on multiplex Cryoimmunostaining™ in FNA cytology.

Open DOI →
2026

Cryophore™ multi-site IVDR validation

PDPROJ-55-VR-001 / PDPROJ-55-VR-007

Prospective validation at Halle and Frankfurt, with 100% concordance reported across all twelve antibodies after OOE resolution.

Validation summary →
Reference sites

Implementation context and resources available on request.

Reference adoption across Germany, Singapore, and Slovenia.

●

Frankfurt, DE

Krankenhaus Nordwest - routine implementation listed from 2023.

●

Bochum, DE

Augusta Hospital - routine implementation listed from 2023.

●

Singapore, SG

Singapore General Hospital and National Cancer Centre Singapore - listed reference sites.

●

Halle, DE

Krankenhaus St. Elisabeth & St. Barbara - routine implementation listed from 2024.

●

Ljubljana, SL

Institute of Oncology Ljubljana - routine implementation listed from 2024.

●

Bangkok, TH

X-ZELL operations, lab, and clinic bridge the commercial and clinical footprint.

Evidence

Need source-level evidence for review?

The evidence dossier page summarizes the documents and topics that qualified institutions can request.

⚠

Evidence note: Clinical performance must be established in the intended patient-specimen context. Product availability, regulatory status, and intended use may vary by market. Please contact X-ZELL for current documentation.